Roche’s Phesgo (pertuzumab/trastuzumab) is one of the half dozen medicines that the European Medicines Agency’s human medicines committee (CHMP) has recommended for approval at its November 2020 meeting. Phesgo has been endorsed as a treatment for early and metastatic breast cancer. Administered as a subcutaneous, fixed-dose combination of pertuzumab and …
Read More »
Medicosnext